中泰证券股份有限公司 关于辰欣药业股份有限公司 使用闲置募集资金进行现金管理的核查意见 中泰证券股份有限公司（以下简称"中泰证券"或"保荐机构"）作为辰欣药业 股份有限公司（以下简称"辰欣药业"或"公司"）首次公开发行股票并在上海证券 交易所上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证券交 易所股票上市规则》、《上市公司监管指引第 2 号—上市公司募集资金管理和使用 的监管要求》和《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等有关规定，对公司使用闲置募集资金进行现金管理的事项进行了核查，并出具 核查意见如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于核准辰欣药业股份有限公司首次公开发行 股票的批复》（证监许可[2017]1660 号）核准，公司向社会公开发行人民币普通 股（A 股）10,000 万股，每股发行价格为人民币 11.66 元，募集资金总额为 1,166,000,000.00 元，扣除发行费用后，募集资金净额为 1,110,346,836.79 元。以 上募集资金已全部到位，并经大信会计师事务所（特殊普通合伙）出具的大信验 字[2017]第 3-00 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2023-050 辰欣药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 28 日(星期一)至 9 月 1 日(星期五)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过辰欣药业股份有限公司（以 下简称"公司"）邮箱 cxyy@cisenyy.com 进行提问，公司将在说明会上对投资者 普遍关注的问题进行回答。 公司已于 2023 年 8 月 25 日发布公司 2023 年半年度报告，为便于广大投资 者更全面深入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 9 月 5 日上午 09:00-10:00 举行 2023 年半年度业绩说明会，就投资者关心的 问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司 ...

辰欣药业股份有限公司独立董事 关于第四届董事会第二十一次会议相关事项的独立意见 根据《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》和《公 司章程》的有关规定，我们作为辰欣药业股份有限公司（以下简称"公司"）的 独立董事，对公司第四届董事会第二十一次会议审议的有关议案进行了审查，发 表意见如下： 一、《关于公司 2023 年半年度募集资金存放与实际使用情况的议案》的独 立意见 经审议，我们认为：公司编制的《关于公司 2023 年半年度募集资金存放与 实际使用情况的专项报告》真实反映了公司 2023 年半年度募集资金存放与实际 使用情况，公司 2023 年半年度募集资金存放与实际使用情况符合中国证监会《上 市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》的相关规 定，不存在变相改变募集资金用途和损害股东利益的情况，不存在募集资金存放 和使用违规的情形。 我们一致同意该议案。 二、《关于公司使用闲置募集资金进行现金管理的议案》的独立意见 经审议，我们认为：本次的募集资金现金管理额度及决策均符合《上市公司 监管指引第 2 号—上市公司募集资金管理和使用的监管要求》、《公司章程》和 《公司 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2023-048 辰欣药业股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 委托理财受托方：商业银行等金融机构 理财金额：最高额度不超过人民币40,000万元。 委托理财产品类型：安全性高、流动性好的保本型银行理财产品。 委托理财期限：使用期限为自2023年8月18日起12个月。 履行的审议程序：辰欣药业股份有限公司（以下简称"公司"或"辰欣药业"） 于2023年8月24日召开了第四届董事会第二十一次会议，会议审议通过了《关于 公司使用闲置募集资金进行现金管理的议案》，公司独立董事发表了同意意见。 本次投资额度在董事会权限范围内，无须提交公司股东大会审议，由公司董 事长行使该项投资决策权并签署相关合同文件，具体操作授权公司相关部门办 理。现将相关事项公告如下： 一、募集资金的基本情况 1、经中国证券监督管理委员会《关于核准辰欣药业股份有限公司首次公开 发行股票的批复》（证监许可【2017】1660号） ...

辰欣药业股份有限公司（以下简称"公司"）于2023月3月30日召开了第四届董事会 第十八次会议，审议通过了《关于公司变更注册资本暨修订＜公司章程＞的议案》，同意 公司的注册资本由 453,263,000元人民币减少至 453,254,000元人民币。根据公司2020 年第三次临时股东大会审议通过的《关于提请公司股东大会授权董事会办理股权激励计划 有关事项的议案》的授权，本次变更事项无需提交公司股东大会审议，由公司董事会根据 授权办理相关工商变更登记等手续。具体内容详见公司于2023年3月31日在上海证券交易 所网站 (www.sse.com.cn) 及指定信息披露媒体上披露的《辰欣药业股份有限公司关于变 更注册资本暨修订＜公司章程＞的公告》（公告编号：2023-018）。 2023年7月28日，公司在上海证券交易所网站 (www.sse.com.cn) 及指定信息披露媒 体上披露了《辰欣药业股份有限公司关于股权激励限制性股票回购注销实施公告》（公告 编号：2023-044），本次回购注销日期为2023年8月1日。注销完成后，公司及时办理了相 关工商变更登记手续。 目前，公司已完成了变更注册资本的工商变更登记以 ...

辰欣药业股份有限公司 CISEN PHARMACEUTICAL CO., LTD. （济宁高新区同济科技工业园） 首次公开发行股票招股说明书 （申报稿） 保荐机构（主承销商） （山东省济南市经七路 86 号） 辰欣药业股份有限公司招股说明书（申报稿） 辰欣药业股份有限公司招股说明书（申报稿） 发行价，或者上市后 6 个月期末收盘价低于发行价，持有公司 股票的锁定期限自动延长 6 个月；如遇除权、除息事项，上述 发行价作相应调整。 4、乾鼎投资、昆吾九鼎、东阳昊润、龙邦贸易、智仕九鼎、 宝寿九鼎、兴贤九鼎、盛世九鼎、卓兴九鼎及赵白雪等 21 名自 然人股东承诺：自公司股票上市之日起十二个月内不转让或者 委托他人管理其本次发行前已持有的发行人股份，也不由发行 人回购其持有的股份。 5、本次发行前间接持有公司股份的董事、监事或高级管理 人员韩延振、郝留山、卢秀莲、刘霁、张祥林、李峰、樊月玲、 张斌承诺：自公司股票上市之日起三十六个月内，不转让或者 委托他人管理其本次发行前间接持有的公司股份，也不由发行 人回购其间接持有的股份。间接所持股票在锁定期满后两年内 减持的，减持价格不低于发行价；公司上市后 6 个月内如公司 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥1,134,403,107.24, representing a year-on-year increase of 30.43%[6] - Net profit attributable to shareholders was ¥155,850,307.28, marking a significant increase of 61.09% compared to the same period last year[6] - The basic earnings per share (EPS) for the quarter was ¥0.34, reflecting a growth of 61.9% year-on-year[7] - Operating profit for Q1 2023 was ¥170,949,622.20, up 64.8% from ¥103,598,487.16 in Q1 2022[22] - Net profit for Q1 2023 was ¥157,206,040.09, representing a 62.6% increase compared to ¥96,618,150.94 in Q1 2022[22] - Total revenue for Q1 2023 reached ¥1,134,403,107.24, a 30.5% increase from ¥869,770,720.65 in Q1 2022[21] - The company reported a total profit of ¥164,037,059.46 for Q1 2023, compared to ¥60,760,141.40 in Q1 2022, indicating strong financial performance[32] Cash Flow and Assets - The net cash flow from operating activities was ¥99,912,686.58, which is an increase of 105.39% compared to the previous year[6] - Operating cash flow for Q1 2023 was ¥955,357,247.48, an increase from ¥712,736,374.06 in Q1 2022[24] - Cash flow from operating activities for Q1 2023 was ¥98,805,509.39, significantly higher than ¥11,879,395.65 in Q1 2022[35] - The company reported a net cash outflow from investing activities of approximately ¥186.14 million, slightly improved from a net outflow of ¥196.19 million in Q1 2022[25] - The company reported a net cash outflow from investing activities of ¥183,974,699.16 in Q1 2023, an improvement from a net outflow of ¥204,594,844.55 in Q1 2022[35] - Total assets at the end of the reporting period amounted to ¥7,165,803,934.34, up 5.15% from the end of the previous year[7] - Total assets as of March 31, 2023, are ¥7,165,803,934.34, compared to ¥6,815,073,080.14 at the end of 2022[17] - Total current assets as of March 31, 2023, amount to ¥5,058,311,975.67, an increase from ¥4,744,959,783.92 as of December 31, 2022[16] - The company’s total equity as of March 31, 2023, was approximately ¥5.06 billion, up from ¥4.91 billion at the end of 2022, indicating a growth of 3.1%[29] Research and Development - The company's R&D expenses increased by 41.37% due to higher investment in new product development during the quarter[9] - Research and development expenses for Q1 2023 totaled ¥91,770,882.19, up 41.3% from ¥64,917,148.86 in Q1 2022[22] - Research and development expenses increased to ¥77,150,126.75 in Q1 2023, compared to ¥59,518,278.36 in Q1 2022, reflecting a focus on innovation[31] Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,941[12] - The largest shareholder, Chenxin Technology Group Co., Ltd., holds 118,891,080 shares, accounting for 26.23% of total shares[12] Liabilities and Financial Position - Total liabilities increased to ¥1,649,732,207.11 from ¥1,459,249,793.23 year-over-year[17] - Total liabilities increased to ¥1.63 billion from ¥1.42 billion, marking a rise of 14.8% year-over-year[29] Inventory and Receivables - Accounts receivable increased to ¥735,505,457.86 from ¥716,164,071.35 year-over-year[16] - The company’s inventory increased to ¥551.78 million from ¥473.71 million, reflecting a rise of 16.5% year-over-year[27] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to sustain growth[9]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603367 证券简称：辰欣药业 公告编号：2023-024 辰欣药业股份有限公司 关于召开 2022 年度业绩说明会的公告 http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 7 日(星期五)至 4 月 12 日(星期三)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过辰欣药业股份有限公司（以 下简称"公司"）邮箱 cxyy@cisenyy.com 进行提问，公司将在说明会上对投资者 普遍关注的问题进行回答。 公司已于 2023 年 3 月 31 日发布公司 2022 年度报告，为便于广大投资者更 全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 4 月 13 日上午 09:00-10:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交 流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 202 ...

Financial Performance - The company achieved an operating revenue of RMB 4.066 billion in 2022, representing a year-on-year increase of 7.49%[24]. - The net profit attributable to shareholders was RMB 350.07 million, an increase of 4.77% compared to the previous year[24]. - The net profit after deducting non-recurring gains and losses was RMB 331.44 million, reflecting a growth of 10.32% year-on-year[24]. - The cash flow from operating activities amounted to RMB 258.35 million, up by 10.59% from the previous year[24]. - The total assets of the company reached RMB 6.815 billion at the end of 2022, an increase of 7.09% compared to the end of 2021[24]. - The basic earnings per share were RMB 0.77, a 4.05% increase from the previous year[25]. - The weighted average return on equity was 6.76%, slightly up from 6.73% in 2021[25]. - The company reported a total profit of RMB 366 million for the year, which is an 8.94% increase year-on-year[35]. - The company reported a significant increase in financial income, contributing to a reduction in financial expenses by 206.86%[58]. - The total revenue for the year 2022 reached approximately ¥4.05 billion, with a year-on-year increase of 7.32%[61]. Dividend Policy - The company plans to distribute a cash dividend of 3.35 RMB per 10 shares, totaling approximately 151.68 million RMB based on 452,775,129 shares[5]. - The total cash dividend amount distributed was approximately ¥151.68 million, which represents 43.33% of the net profit attributable to ordinary shareholders[164]. - The company implemented a cash dividend policy, distributing a cash dividend of 3.00 RMB per 10 shares, amounting to a total of 135,850,238.70 RMB, which represents 40.66% of the net profit attributable to shareholders[155][156]. - The company’s profit distribution policy emphasizes stable and continuous cash dividends, with a focus on maintaining a balance between shareholder returns and sustainable development[157][158]. Research and Development - The company is committed to enhancing its product structure through internal R&D and collaborations with external research institutions, focusing on high-margin products[36]. - The company has engaged in research collaborations with multiple prestigious institutions, facilitating new product development[53]. - R&D investment accounted for over 8% of operating revenue, supporting the company's sustainable development[56]. - The company invested CNY 335 million in R&D in 2022, maintaining an R&D expenditure ratio of over 8% of sales revenue[92]. - There are over 100 ongoing R&D projects focusing on complex injectables, controlled-release oral solid formulations, and other therapeutic areas[93]. - The company is actively seeking collaborations for R&D projects under the new MAH policy to enhance its product pipeline[92]. - The company has completed preclinical research for a new drug targeting autoimmune inflammation and an antiviral drug, both of which have applied for Pre-IND[94]. - The company has established R&D subsidiaries in India, Tianjin, and Jinan to enhance innovation and resource sharing[92]. Market Expansion and Sales Strategy - The company continues to focus on market demand and has been enhancing its sales management system and service tools[35]. - In 2022, the company established a nationwide sales network for new and generic drugs, focusing on OTC drugs, special medical foods, and traditional Chinese medicine, creating three new growth points[36]. - The company expanded its sales team and implemented a four-level training program to enhance the quality of its sales personnel, aiming for professional and precise market services[36]. - The sales model includes both direct sales to hospitals and retail pharmacies, as well as distribution through pharmaceutical companies[51]. - The company plans to focus on expanding its market presence and enhancing its product development strategies in the upcoming year[61]. - The company is investing $200 million in research and development for new technologies over the next two years[85]. - Market expansion efforts include entering two new countries, which are expected to generate an additional $50 million in revenue[86]. Corporate Governance - The company has implemented a governance structure that complies with relevant laws and regulations, ensuring effective internal control and protection of shareholder rights[121]. - The board of directors has established four specialized committees to provide scientific and professional opinions for decision-making[122]. - The company has maintained independence from its controlling shareholder, ensuring no adverse impact on its operations[123]. - The company has adhered to information disclosure regulations, ensuring transparency and equal access to information for all shareholders[124]. - The company held multiple shareholder meetings, ensuring compliance with legal requirements and timely disclosure of resolutions[126]. Environmental Management - The company has established an environmental management department to adapt to stringent environmental regulations and improve operational management capabilities[119]. - The company has received various environmental impact approvals for its projects, demonstrating compliance with regulatory requirements[178]. - The company has implemented an environmental self-monitoring plan, with third-party testing confirming that all pollutant indicators meet discharge standards[183]. - The company has committed to continuous improvement in waste management, with all hazardous waste being handled by authorized environmental firms[190]. - The company has installed activated carbon treatment equipment for exhaust emissions, ensuring compliance with environmental standards[176]. Risk Management - The company faces risks related to macroeconomic conditions and policy changes that could impact its operations and profitability[118]. - Fluctuations in raw material prices pose a significant risk to the company's production costs and profit margins, necessitating proactive procurement strategies[118]. - The company faces risks from intensified industry competition, particularly in the generic and innovative drug sectors, and will focus on maintaining competitive advantages[119]. Employee Development - The company conducted over 1,000 training sessions in 2022, with an average of 50 hours of training per employee, significantly enhancing the overall quality of its workforce[153]. - The company has established a comprehensive training management system, focusing on various functional modules including R&D, sales, quality, production, and safety[153]. - The total number of employees in the parent company is 2,905, and the total number of employees in major subsidiaries is 508, resulting in a combined total of 3,413 employees[150].

证券代码：603367 证券简称：辰欣药业 公告编号：2022-075 辰欣药业股份有限公司 关于参加山东辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，做好投资者关系管理工作，辰欣药业股 份有限公司（以下简称"公司"）将参加由山东证监局联合山东上市公司协会等 单位举办的"山东辖区上市公司 2022 年度投资者网上集体接待日"活动，现将 有关事项公告如下： 本次投资者网上集体接待日活动将通过网上平台采取网络远程的方式举行， 投资者可以登录全景网"投资者关系互动平台"（http://ir.p5w.net/）参与本 次活动，活动时间为 2022 年 11 月 16 日（星期三）14:00 至 16:00。 届时公司董事长、总经理、财务总监杜振新先生、董事会秘书续新兵先生及 证券部工作人员将通过网络在线交流形式与投资者就公司治理、经营状况等投资 者关注的问题进行沟通，欢迎广大投资者积极参与。 特此公告。 辰欣药业股份有限公司 董事会 202 ...